Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
Piotr Mróz, Brian Finan, Vasily M. Gelfanov, et al.
Molecular Metabolism (2018) Vol. 20, pp. 51-62
Open Access | Times Cited: 175

Showing 1-25 of 175 citing articles:

Glucagon-like peptide 1 (GLP-1)
Timo D. Müller, Brian Finan, Stephen R. Bloom, et al.
Molecular Metabolism (2019) Vol. 30, pp. 72-130
Open Access | Times Cited: 1306
Anti-obesity drug discovery: advances and challenges
Timo D. Müller, Matthias Blüher, Matthias H. Tschöp, et al.
Nature Reviews Drug Discovery (2021) Vol. 21, Iss. 3, pp. 201-223
Open Access | Times Cited: 688
Function and mechanisms of enteroendocrine cells and gut hormones in metabolism
Fiona M. Gribble, Frank Reimann
Nature Reviews Endocrinology (2019) Vol. 15, Iss. 4, pp. 226-237
Closed Access | Times Cited: 499
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Ricardo J. Samms, Matthew P. Coghlan, Kyle W. Sloop
Trends in Endocrinology and Metabolism (2020) Vol. 31, Iss. 6, pp. 410-421
Open Access | Times Cited: 277
Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake
Alice E. Adriaenssens, Emma K. Biggs, Tamana Darwish, et al.
Cell Metabolism (2019) Vol. 30, Iss. 5, pp. 987-996.e6
Open Access | Times Cited: 243
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
Laurie L. Baggio, Daniel J. Drucker
Molecular Metabolism (2020) Vol. 46, pp. 101090-101090
Open Access | Times Cited: 220
The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: A pathophysiological update
Michael A. Nauck, Daniel R. Quast, Jakob Wefers, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. S3, pp. 5-29
Closed Access | Times Cited: 219
The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling
Qian Zhang, Tenagne D. Challa, Robert Augustin, et al.
Cell Metabolism (2021) Vol. 33, Iss. 4, pp. 833-844.e5
Open Access | Times Cited: 192
GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
Ricardo J. Samms, Michael E. Christe, Kyla Collins, et al.
Journal of Clinical Investigation (2021) Vol. 131, Iss. 12
Open Access | Times Cited: 150
GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
Jens J. Holst, Mette M. Rosenkilde
The Journal of Clinical Endocrinology & Metabolism (2020) Vol. 105, Iss. 8, pp. e2710-e2716
Open Access | Times Cited: 146
Role of the gut–brain axis in energy and glucose metabolism
Hallie Wachsmuth, Savanna N. Weninger, Frank A. Duca
Experimental & Molecular Medicine (2022) Vol. 54, Iss. 4, pp. 377-392
Open Access | Times Cited: 129
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Rola Hammoud, Daniel J. Drucker
Nature Reviews Endocrinology (2022) Vol. 19, Iss. 4, pp. 201-216
Closed Access | Times Cited: 127
Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist
Martin Bossart, Michael Wagner, Ralf Elvert, et al.
Cell Metabolism (2021) Vol. 34, Iss. 1, pp. 59-74.e10
Open Access | Times Cited: 124
The expanding incretin universe: from basic biology to clinical translation
Daniel J. Drucker, Jens J. Holst
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1765-1779
Open Access | Times Cited: 117
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Qiming Tan, Seun Akindehin, Camila E. Orsso, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 104
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Patrick J. Knerr, Stephanie A. Mowery, Jonathan D. Douros, et al.
Molecular Metabolism (2022) Vol. 63, pp. 101533-101533
Open Access | Times Cited: 86
Gut hormone co-agonists for the treatment of obesity: from bench to bedside
Rubén Nogueiras, Michael A. Nauck, Matthias H. Tschöp
Nature Metabolism (2023) Vol. 5, Iss. 6, pp. 933-944
Closed Access | Times Cited: 57
GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications
Jonathan E. Campbell, Timo D. Müller, Brian Finan, et al.
Cell Metabolism (2023) Vol. 35, Iss. 9, pp. 1519-1529
Open Access | Times Cited: 57
Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy
Matthias H. Tschöp, Rubén Nogueiras, Bo Åhrén
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1796-1808
Open Access | Times Cited: 51
Obesity and its comorbidities, current treatment options and future perspectives: Challenging bariatric surgery?
Simon Kloock, Christian G. Ziegler, Ulrich Dischinger
Pharmacology & Therapeutics (2023) Vol. 251, pp. 108549-108549
Open Access | Times Cited: 49
GLP-1-directed NMDA receptor antagonism for obesity treatment
Jonas Petersen, Mette Q. Ludwig, Vaida Juozaityte, et al.
Nature (2024) Vol. 629, Iss. 8014, pp. 1133-1141
Open Access | Times Cited: 38
Targeting the incretin system in obesity and type 2 diabetes mellitus
Saleem Ansari, Bernard Khoo, Tricia Tan
Nature Reviews Endocrinology (2024) Vol. 20, Iss. 8, pp. 447-459
Closed Access | Times Cited: 30
Transforming obesity: The advancement of multi-receptor drugs
Christine M. Kusminski, Diego Pérez–Tilve, Timo D. Müller, et al.
Cell (2024) Vol. 187, Iss. 15, pp. 3829-3853
Closed Access | Times Cited: 24
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Qiyuan Keith Liu
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 16
Glucose-dependent insulinotropic polypeptide (GIP)
Timo D. Müller, Alice E. Adriaenssens, Bo Ahrén, et al.
Molecular Metabolism (2025) Vol. 95, pp. 102118-102118
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top